Kripthonite Therapeutics develops PH1154, a therapy that selectively targets and eliminates hypoxic cancer cells in solid tumors by disrupting their energy metabolism. This approach enhances the effectiveness of existing treatments like radiotherapy and immunotherapy by making tumors more susceptible to these therapies.
Funding
Funding not disclosed
Founders
Product
Problem
Hypoxic cancer cells within solid tumors are resistant to many conventional treatments like radiotherapy, chemotherapy, and immunotherapy, leading to treatment failure and disease recurrence. These cells survive in low-oxygen environments and are difficult to target with existing therapies.
Solution
Kripthonite Therapeutics is developing PH1154, a novel therapeutic agent designed to selectively target and eliminate hypoxic cancer cells by disrupting their energy metabolism. By eradicating these resistant cells, PH1154 aims to enhance the effectiveness of existing cancer treatments, such as radiotherapy and immunotherapy, making tumors more vulnerable to these therapies. Preclinical studies have demonstrated that PH1154 complements radiotherapy by eliminating hypoxic tumor cells, while radiotherapy eradicates the normoxic bulk tumor. This combined approach has the potential to improve patient outcomes by addressing a key mechanism of treatment resistance.
Target Audience
The primary target audience includes cancer patients with solid tumors containing hypoxic cells, as well as oncologists and researchers seeking to improve treatment outcomes for these patients.
Features
- Selectively targets and eliminates hypoxic cancer cells within solid tumors.
- Disrupts the energy metabolism of hypoxic cells through a novel mechanism of action.
- Enhances the effectiveness of radiotherapy and immunotherapy.
- Demonstrated synergistic effect with radiotherapy in preclinical studies.